Insider purchase details
David Young, who serves as President of Research & Development at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), purchased 1,810 shares of the companys common stock on March 31, 2026. The shares were acquired at $2.535 each, making the total transaction value $4,588. After this transaction, Young now directly holds 10,562 shares.
Indirect holdings and ownership structure
In addition to his direct ownership, Young has indirect interests in Processa equity through multiple vehicles: 1,242 shares are attributable to the Young-Plaisance Revocable Trust, 432 shares are held via Family Entities, and 742 shares are held through CorLyst, LLC. These indirect positions are part of Youngs broader ownership footprint in the company.
Company size and balance sheet snapshot
Processa Pharmaceuticals is a microcap biotech, with a market capitalization of $6.97 million. The companys balance sheet position is noted as having more cash than debt, a metric sometimes used to gauge near-term liquidity for small clinical-stage companies.
Clinical program update
Separately, Processa has completed enrollment and dosing for its Phase 2 clinical study of NGC-Cap in patients with advanced or metastatic breast cancer. The randomized study includes 20 patients and will move forward with a planned interim analysis. The trial compares the combination regimen of PCS6422 plus capecitabine - referred to as NGC-Cap - against capecitabine alone. All participants had received at least one prior cancer therapy, with the median number of previous regimens reported as between two and three.
Context and what to watch next
The insider purchase increases Youngs direct stake modestly while leaving his indirect holdings intact through established family and trust vehicles. The companys completion of dosing in the Phase 2 trial triggers an upcoming interim analysis that will be important to follow. Given Processas small market capitalization, developments from the clinical program and any material balance sheet changes could be influential for investor focus and trading liquidity.
Note on source material
This report is a factual account of the disclosed insider transaction, ownership details, reported market capitalization, balance sheet characterization, and the Phase 2 study status as provided in the original company disclosures.